Seasonal Influenza Vaccines Epidemiology Analysis and Forecast to 2032

1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 7MM forecast methodology
2.4.1 Sources
2.4.2 Forecast assumptions and methods
2.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM
2.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by EF
2.4.5 Forecast assumptions and methods: hospitalizations for acute HF
2.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation
2.4.7 Forecast assumptions and methods: hospital LoS days for acute HF hospitalizations
2.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization
2.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM
2.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by EF
2.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by NYHA classes
2.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF-PEF (LVEF =50%) by NYHA class
2.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class
2.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF-REF (LVEF < 40%) by NYHA class
2.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by ACCF/AHA stages
2.5 Epidemiological forecast for heart failure (2022-32)
2.5.1 Diagnosed incident cases of HF
2.5.2 Age-specific diagnosed incident cases of HF
2.5.3 Sex-specific diagnosed incident cases of HF
2.5.4 Diagnosed incident cases of HF by EF
2.5.5 Hospitalizations for acute HF
2.5.6 Acute HF hospitalizations based on presentation
2.5.7 Hospital LoS for acute HF
2.5.8 Re-admissions within 30 days post-discharge after acute HF
2.5.9 Diagnosed prevalent cases of HF
2.5.10 Age-specific diagnosed prevalent cases of HF
2.5.11 Sex-specific diagnosed prevalent cases of HF
2.5.12 Diagnosed prevalent cases of HF by EF
2.5.13 Diagnosed prevalent cases of HF by NYHA classes
2.5.14 Diagnosed prevalent cases of HF-PEF (LVEF =50%) by NYHA class
2.5.15 Diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class
2.5.16 Diagnosed prevalent cases of HF-REF (LVEF < 40%) by NYHA class
2.5.17 Diagnosed prevalent cases of HF by ACCF/AHA stages
2.6 Discussion
2.6.1 Epidemiological forecast insight
2.6.2 COVID-19 impact
2.6.3 Limitations of the analysis
2.6.4 Strengths of the analysis

3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Vice President of Disease Intelligence and Epidemiology

• Contact the Publisher

Table 1: Summary of updated data types
Table 2: Risk factors and comorbidities for SI

Figure 1: 7MM, diagnosed incident cases of lab-confirmed influenza, both sexes and all ages, N, 2022 and 2032
Figure 2: 7MM, SI vaccinated cases, both sexes and all ages, N, 2022 and 2032
Figure 3: 7MM, diagnosed incidence of lab-confirmed SI, both sexes, cases per 100,000 population, all ages, 2012-32
Figure 4: 7MM, SI vaccination rate, both sexes, %, all ages, 2012-32
Figure 5: 7MM, sources used to forecast diagnosed incident cases of ILI
Figure 6: 7MM, sources used to forecast diagnosed incident cases of lab-confirmed SI
Figure 7: 7MM, sources used in SI vaccinated population
Figure 8: 7MM, diagnosed incident cases of ILI, N, both sexes, all ages, 2022Figure 9: 7MM, diagnosed incident cases of ILI by age, N, both sexes, 2022
Figure 10: 7MM, diagnosed incident cases of ILI by sex, N, all ages, 2022Figure 11: 7MM, diagnosed incident cases of lab-confirmed SI, N, both sexes, all ages, 2022
Figure 12: 7MM, diagnosed incident cases of lab-confirmed SI by age, N, both sexes, 2022
Figure 13: 7MM, diagnosed incident cases of lab-confirmed SI by sex, N, all ages, 2022
Figure 14: 7MM, SI vaccinated population, N, both sexes, all ages, 2022
Figure 15: 7MM, SI vaccinated population by age, N, both sexes, 2022